Percentage of free serum prostate-specific antigen as a predictor of pathologic features of prostate cancer in a screening population

Urology

Volumn 51, Issue 4, 1998, Pages 558-565

  Arcangeli, Carlos G ^b   Humphrey, Peter A ^b   Smith, Deborah S ^b   Harmon, Taz J ^b   Shepherd, David L ^b   Keetch, David W ^b   Catalona, William J ^a  

^a Division of Urologic Surgery   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE MARKER; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PRACTICE GUIDELINE; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RISK ASSESSMENT; TREATMENT PLANNING; TUMOR VOLUME;

AGED; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 0031922293     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00035-1     Document Type: Article

References (27)

1. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, deKernionJB, Ratliff TL, Kavoussi LR, Dalkin BL, et al: Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 151: 1283-1290, 1994.
2. Catalona WJ, Smith DS, Ratliff TL, and Basler JW: Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 270: 948-954, 1993.
3. Brawer MK, Chetner MP, Beattie J, Buchner DM, Vessella RL, and Lange PH: Screening for prostatic carcinoma with prostate specific antigen. J Urol 147(3 Pt 2): 841-845, 1992.
4. Stenman U-H, Hakama M, Knekt P, Aromaa A, Teppo L, and Leinonen J: Serum concentrations of prostate specific antigen and its complex with alphal-antichymotrypsin before diagnosis of prostate cancer. Lancet 344: 1594-1598, 1994.
5. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, and Nadler RB: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 274: 1214-1220, 1995.
6. Bangma CH, Kranse R, Blijenberg BG, and Schroeder FH: The value of screening tests in the detection of prostate cancer. Part I: results of a retrospective evaluation of 1726 men. Urology 46: 773-778, 1995.
7. Luderer AA, Chen Y-T, Soriano TF, Kramp WJ, Carlson G, Cuny C, Sharp T, Smith W, Petteway J, Brawer MK, et al: Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology 46: 187-194, 1995.
8. Elgamal AA, Cornillie FJ, Van Poppel HP, Van de Voorde WM, McCabe R, and Baert LV: Free-to-total prostate specific antigen ratio as a single test for detection of significant stage T1c prostate cancer. J Urol 156: 1042-1049, 1996.
9. Catalona WJ, Smith DS, and Ornstein DK: Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination: enhancement of specificity with free PSA measurements. JAMA 277: 1452-1455, 1997.
10. Smith DS, and Catalona WJ: The nature of prostate cancer detected through prostate specific antigen based screening. J Urol 152(5 Pt 2): 1732-1736, 1994.
11. Humphrey PA, Keetch DW, Smith DS, Shepherd DL, and Catalona WJ: Prospective characterization of pathologic features of prostatic carcinomas detected via serum prostate specific antigen-based screening. J Urol 155: 816-820, 1996.
12. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, and Andriole GA: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324: 1156-1161, 1991.
13. Humphrey PA, Baty J, and Keetch DW: Relationship between serum prostate specific antigen, needle biopsy findings, and histopathologic features of prostate cancer in radical prostatectomy tissues. Cancer 75(suppl): 1842-1849, 1995.
14. Terris MK, and Stamey TA: Determination of prostate volume by transrectal ultrasound. J Urol 145: 984-987, 1991.
15. Gleason DF: Histologic grading of prostate cancer: a perspective. Hum Pathol 23: 273-279, 1992.
16. Humphrey PA, and Vollmer RT: Intraglandular tumor extent and prognosis in prostatic carcinoma: application of a grid method to prostatectomy specimens. Hum Pathol 21: 799-804, 1990.
17. Ohori M, Wheeler TM, Dunn JK, Stamey TA, and Scardino PT: The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol 152(5 Pt 2): 1714-1720, 1994.
18. Humphrey PA, Frazier HA, Vollmer RT, and Paulson DF: Stratification of pathologic features in radical prostatectomy specimens that are predictive of elevated initial postoperative serum PSA levels. Cancer 71: 1821-1827, 1993.
19. Elgamal AA, Van Poppel HP, Van de Voorde WM, Van Dorpe JA, Oyen RH, and Baert LV: Impalpable invisible stage T1c prostate cancer: characteristics and clinical relevance in 100 radical prostatectomy specimens - a different view. J Urol 157: 244-250, 1997.
20. Hosmer DW, and Lemeshow S: Applied Logistic Regression. New York, Wiley, 1989, pp 16 and 89.
21. Epstein JI, Walsh PC, Carmichael M, and Brendler CB: Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271: 368-374, 1994.
22. Epstein JI, Partin AW, Saurageot J, and Walsh PC: Prediction of progression following radical prostatectomy: a multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol 20: 286-292, 1996.
23. Carter HB, Partin AW, Luderer AA, Metter EJ, Landis P, Chan DW, Fozard JL, and Pearson JD: Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. Urology 49: 379-384, 1997.
24. Pannek J, Subong ENP, Jones KA, Marschke PL, Epstein JI, Chan DW, Carter HB, Luderer AA, and Partin AW: The role of free/total prostate-specific antigen ratio in the prediction of final pathologic stage for men with clinically localized prostate cancer. Urology 48: 51-54, 1996.
25. Bangma CH, Kranse R, Blijenberg BG, and Schroeder FH: The free-to-total serum prostate specific antigen ratio for staging prostate carcinoma. J Urol 157: 544-547, 1997.
26. Ornstein DK, Smith DS, Rao GS, Basler JW, Ratliff TL, and Catalona WJ: Biological variation of total, free and percent free serum prostate specific antigen levels in screening volunteers. J Urol 157: 2179-2182, 1997.
27. Jacobsen SJ, Katusic SK, Bergstralh EJ, Oesterling JE, Ohrt D, Klee GG, Chute CG, and Lieber MM: Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. JAMA 274: 1445-1449, 1995.